Skip to main content
Walter Kaufmann, MD, Cardiology, Port Jervis, NY

Walter Ernst Kaufmann MD

Adult Congenital Heart Disease, Cardiac Electrophysiology


Physician

Join to View Full Profile
  • 161 E Main St# CommunitPort Jervis, NY 12771

  • Phone+1 845-858-2666

  • Fax+1 845-858-2662

Join Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
    You already have 1 invite waiting!
  • Read the latest clinical news, personalized to your specialty.

Summary

  • Dr. Walter Kaufmann, MD is a cardiologist in Port Jervis, New York. He is currently licensed to practice medicine in New York and New Jersey. He is affiliated with Bon Secours Community Hospital and Westchester Medical Center.

Education & Training

  • Rutgers Health/Newark Beth Israel Medical Center
    Rutgers Health/Newark Beth Israel Medical CenterFellowship, Cardiovascular Disease, 1980 - 1982
  • Rutgers Health/New Jersey Medical School
    Rutgers Health/New Jersey Medical SchoolResidency, Internal Medicine, 1977 - 1980
  • Rutgers New Jersey Medical School
    Rutgers New Jersey Medical SchoolClass of 1977

Certifications & Licensure

  • NJ State Medical License
    NJ State Medical License Current
  • NY State Medical License
    NY State Medical License 1982 - 2026
  • Internal Medicine
    American Board of Internal Medicine Internal Medicine
  • Cardiovascular Disease
    American Board of Internal Medicine Cardiovascular Disease

Publications & Presentations

PubMed

Press Mentions

  • Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (Blarcamesine) in Rett Syndrome
    Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (Blarcamesine) in Rett SyndromeNovember 6th, 2019
  • Anavex Life Sciences Presented at the 6th Annual European Rett Syndrome Conference Preliminary Clinical Efficacy Data from the U.S. Rett Syndrome Phase 2 ANAVEX®2-73 Study
    Anavex Life Sciences Presented at the 6th Annual European Rett Syndrome Conference Preliminary Clinical Efficacy Data from the U.S. Rett Syndrome Phase 2 ANAVEX®2-73 StudySeptember 27th, 2019
  • Anavex Life Sciences Reports Fiscal 2019 First Quarter Financial Results and Provides Clinical Study Updates
    Anavex Life Sciences Reports Fiscal 2019 First Quarter Financial Results and Provides Clinical Study UpdatesMarch 28th, 2019